Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2018 Oct 17;28(1):174–182. doi: 10.1158/1055-9965.EPI-18-0483

Figure 1. Analysis of biomarkers in sera from PDAC patients, benign conditions, and healthy controls.

Figure 1.

A-G, Concentrations of OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27 and CA19–9 in PDAC patients, benign conditions, and healthy controls. Only serum levels of biomarkers demonstrating significant differences between pancreatitis, IPMN, and PDAC early stage, (or benign and PDAC) are asterisked (Mann-Whitney U test). Bars indicate median value. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.